Our mission is to advance life science for better human health with next generation protein sequencing.
Rapid Novor Inc is the world’s leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence the antibody proteins without needing to access the cell line.
As a University of Waterloo spin-off, the company is building its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company’s REmAb™ antibody protein sequencing service has allowed the accurate sequencing of any given antibody proteins routinely. The company’s WILD™ service is the first commercially available service that can accurately distinguish the isomeric Isoleucine and Leucine using mass spectrometry.
For over a decade people have had the impression that de novo peptide sequencing with MS/MS is slow. Dr. Ma, as a bioinformatician who worked on this problem for years, was deeply disturbed and wanted to make a change. Starting from January 2015, Dr. Ma has devoted himself to a new de novo sequencing tool, Novor. The outcome of this dedication is rewarding: Novor achieved a speed of 300 spectra per second with a MacBook Pro laptop computer, with accuracy better than other available tools.
With an order of magnitude faster than any other software out there, and a speed surpassing all modern mass spectrometers in the market, the software may enable applications that are not possible in the past. Thus, Rapid Novor Inc was founded to make it happen.